Latest Articles and Analysis

Systemic barriers preventing HCV-infected people from accessing available cure.

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

ADA conflicts with state prescription drug affordability board operations.

First year results of Together TakeMeHome HIV self-testing distribution program.

HCV co-infection in HIV-positive MSM: treatment barriers through ADAPs and policy recommendations.

FTC enforcement against hospital mergers and implications for costs and access.

Potential harms of state PDABs on HIV treatment access and ending the epidemic.

Unintended consequences of Inflation Reduction Act drug pricing provisions.

Stigma, discrimination, and resilience in LGBTQIA+ communities' fight for health equity.

CDC doxycycline post-exposure prophylaxis guidance for STI prevention amid political debate.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Analysis of ADA protections for PLWHA including workplace discrimination and HIV criminalization.

HHS proposed viral hepatitis quality measures for Medicaid and health equity implications.

Barriers to HIV care for formerly incarcerated people and continuity strategies.

Mpox emergency response analysis and lessons for future equitable public health crises.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Celebrity HIV misinformation directly impacts testing rates and perpetuates harmful stigma.

Declining HCV infections but persistent treatment barriers and disparities remain.

Copay accumulator schemes and Essential Health Benefits loophole; Louisiana as model.

WHO updated hepatitis B guidelines: implications for global HBV testing and treatment.